Register for our free email digests:
Iterum Therapeutics Limited
http://www.iterumtx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Iterum Therapeutics Limited
Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Deal Watch: Bausch Health Takes Option To Allegro Dry AMD Candidate
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Iterum Anxiously Awaiting Other Results After SURE 3 Failure
Iterum’s antibiotic sulopenem missed its endpoint by the equivalent of one patient. The company believes the Phase III data could still support its NDA for urinary tract infections.
QIDP Roundup: Familiar Names Dominate 2019 Designations
US FDA's Qualified Infectious Disease Product program is growing slowly, but still growing.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals